文献速递类风湿关节炎

单条目患者报告的治疗困扰测量在类风湿关节炎中的效度与实用性:一项横断面OMERACT研究

Validity and utility of a single-item patient-reported measure of treatment-related bother in rheumatoid arthritis: A cross-sectional OMERACT study.
PubMed 文献 · Semin Arthritis Rheum · 2026-04-19

该横断面网络调查纳入560例类风湿关节炎患者,评估FACIT系统中改良单条目副作用困扰测量(GP5)的结构效度,并与PRO-CTCAE报告的症状性副作用比较。多重对应分析显示保留一个维度即可捕捉最有意义的信息,该总体副作用负担评分反映受多种症状性副作用影响的广泛概念,各副作用影响微弱至可忽略。单条目困扰测量可能作为有用的总结指标。

要点

  • 单条目副作用困扰测量(GP5)与多种症状性副作用构成的总体负担评分相关。
  • 多重对应分析显示仅保留一个维度即可捕捉最有意义的信息。
  • 总体副作用负担评分反映广泛概念,各症状性副作用影响微弱至可忽略。

核心结论

  • 单条目副作用负担测量可能作为有用的总结指标,反映RA患者症状性副作用的影响。

研究设计与样本

  • 横断面网络调查纳入560例类风湿关节炎患者,评估改良单条目副作用困扰测量(GP5)的结构效度。

主要发现

  • 多重对应分析将80种症状性副作用降维,碎石图显示第一个维度后有明显拐点,仅保留一个维度。
  • 总体副作用负担评分反映受多种症状性副作用影响的广泛概念,各副作用影响微弱至可忽略。
  • 采用Spearman rho检验关键维度、单个条目、当前副作用总和与单条目困扰测量之间的关联。

临床怎么用

  • 单条目副作用困扰测量可作为RA患者治疗相关副作用总体负担的简要总结指标。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To assess the construct validity of a modified single-item measure of bother due to side effects (the GP5 item) from the Functional Assessment of Chronic Illness Therapy (FACIT) system by comparing it to current symptomatic side effects from the Patient-Reported Outcomes of the Common Terminology Criteria for Adverse Events (PROCTCAE) reported by patients with rheumatoid arthritis (RA). METHODS: Through a cross-sectional, web-based survey we collected information on the frequency of symptomatic side effects and bother from side effects related to RA medications. We applied multiple correspondence analysis (MCA) to reduce 80 symptomatic side effects into key dimensions (≥5% of the total variance each). We then examined associations among key dimensions, individual items, the sum of current side effects, and the single-item bother measure using Spearman rho. RESULTS: A total of 560 patients participated in the online survey. Our scree plot showed a clear elbow point after the first dimension, indicating that keeping just one dimension captured the most meaningful information. This overall side effect burden score appeared to reflect a broad concept influenced by a variety of symptomatic side effects, each having only a negligible to weak impact. CONCLUSIONS: Our results may indicate that individuals have diverse experiences of side effects, allowing the global index to capture these variations, even when they differ across patients. Thus, a single-item burden measure to side effects can potentially serve as a useful summary indicator, shedding light on the impact of symptomatic side effects experienced by RA patients.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Berthelsen DB, Haugegaard T, Kamso MM, et al. Validity and utility of a single-item patient-reported measure of treatment-related bother in rheumatoid arthritis: A cross-sectional OMERACT study. Semin Arthritis Rheum. 2026. PMID: 42034888. doi:10.1016/j.semarthrit.2026.152983

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。